AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34039021 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine levels
Number of subjects: 2
Study 34039021 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 34039031 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS) as a continuous variable
Number of subjects: 12792
Study 34039031 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS) as a categorical variable (highest tertile)
Number of subjects: 12792
Study 34039031 — intervention group
Group type: COMPARATOR
Intervention: Conventional model
Number of subjects: 12792
Study 34039031 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional model plus PRS
Number of subjects: 12792
Study 34039031 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous PRS
Number of subjects: 12792
Study 34039031 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous net reclassification index after adding PRS to the conventional model
Number of subjects: 12792
Study 34039285 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma uric acid (PUA) (373 µmol/l)
Number of subjects: 606
Study 34039285 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of plasma uric acid (PUA) (234 µmol/l)
Number of subjects: 606
Study 34039285 — intervention group
Group type: EXPERIMENTAL
Intervention: PUA concentration
Number of subjects: 606
Study 34039337 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care professionals (HCP) perspectives on spiritual concerns and needs
Number of subjects: 76
Study 34039337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain patients (CPP) perspectives on spiritual concerns and needs
Number of subjects: 76
Study 34039337 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonalities and differences in perspectives of HCPs and CPPs
Number of subjects: 76
Study 34039337 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for training and awareness
Number of subjects: 76
Study 34039438 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended therapy (interactive tablet-based home exercise program combined with face-to-face therapy sessions)
Number of subjects: 14
Study 34039578 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver assessments after the death of the individual with DLB
Number of subjects: 0
Study 34039578 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal trend models
Number of subjects: 0
Study 34039578 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver factors assessments
Number of subjects: 0
Study 34039578 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative descriptive analysis
Number of subjects: 0
Study 34039647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 24
Study 34039905 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-rehabilitation contracts (GSCs) combined with abobotulinumtoxinA injections (1500 U)
Number of subjects: 153
Study 34039929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal educational intervention in targeted normoxia
Number of subjects: 0
Study 34039929 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34039930 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case (BC/WC) communication tool
Number of subjects: 86
Study 34040174 — intervention group
Group type: EXPERIMENTAL
Intervention: Berzosertib (90-210 mg) plus cisplatin (day 1) every 3 weeks (Q3W)
Number of subjects: 31
Study 34040175 — intervention group
Group type: EXPERIMENTAL
Intervention: berzosertib + gemcitabine
Number of subjects: 60
Study 34040175 — intervention group
Group type: EXPERIMENTAL
Intervention: berzosertib + gemcitabine + cisplatin
Number of subjects: 60
Study 34040195 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GHT)
Number of subjects: 0
Study 34040195 — intervention group
Group type: EXPERIMENTAL
Intervention: SNORD116 deletion (in knockout mouse model)
Number of subjects: 0
Study 34040195 — intervention group
Group type: EXPERIMENTAL
Intervention: iPSC-derived neurons from a SNORD116-deleted PWS patient
Number of subjects: 0
Study 34040195 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 34040400 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100 mg twice daily)
Number of subjects: 0
Study 34040400 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600-800 mg three times daily)
Number of subjects: 0
Study 34040400 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (375-500 mg twice daily)
Number of subjects: 0
Study 34040605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral gene therapy with recombinant AAV serotype 2/5 (rAAV2/5) coding human NAGLU
Number of subjects: 4
Study 34040886 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (24 sessions over 12 weeks)
Number of subjects: 202
Study 34040886 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 202
Study 34041280 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Insulin Resistance
Number of subjects: 0
Study 34041280 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-insulin resistant patients)
Number of subjects: 0
Study 34041284 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum homocysteine level
Number of subjects: 0
Study 34041459 — intervention group
Group type: COMPARATOR
Intervention: F/TDF (200mg/300mg)
Number of subjects: 99
Study 34041459 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TAF25 (200mg/25mg)
Number of subjects: 99
Study 34041459 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TAF10 (200mg/10mg)
Number of subjects: 99
Study 34041459 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TAF (200mg/25mg)
Number of subjects: 99
Study 34041648 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrasystolic beats
Number of subjects: 56
Study 34041648 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-fluid challenge (50 ml crystalloid infused in 10 seconds)
Number of subjects: 56
Study 34041702 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 7.5 mg
Number of subjects: 371
Study 34041702 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 371
Study 34041702 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 371
Study 34041702 — intervention group
Group type: COMPARATOR
Intervention: Global population (15 mg once daily)
Number of subjects: 371
Study 34041702 — intervention group
Group type: COMPARATOR
Intervention: Global population (30 mg once daily)
Number of subjects: 371
Study 34041706 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin (750.0 mg or 8.2 mg/kg) administered for a median of 26 days (IQR, 12, 42 days)
Number of subjects: 291
Study 34042098 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg subcutaneously (60 mg in obese patients, 20 mg in renal failure)
Number of subjects: 219
Study 34042414 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based 6-minute walking test (6WT)
Number of subjects: 49
Study 34042560 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptional signatures of human peripheral blood mononuclear cells
Number of subjects: 0
Study 34043525 — intervention group
Group type: EXPERIMENTAL
Intervention: CoMET display (AI-based visual risk analytic) along with standard of care
Number of subjects: 10424
Study 34043525 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 10424
Study 34043668 — intervention group
Group type: COMPARATOR
Intervention: Cohort 1
Number of subjects: 0
Study 34043668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2
Number of subjects: 0
Study 34043683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic MRI
Number of subjects: 171
Study 34043683 — intervention group
Group type: COMPARATOR
Intervention: BMB/BMS
Number of subjects: 171
Study 34043683 — intervention group
Group type: COMPARATOR
Intervention: PET/CT
Number of subjects: 171
Study 34043812 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg daily)
Number of subjects: 33
Study 34043894 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (30 μg, two injections, 21 days apart)
Number of subjects: 2260
Study 34043894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2260
Study 34043894 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 2260
Study 34043963 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-vaccination cohort (2010-12)
Number of subjects: 400
Study 34043963 — intervention group
Group type: COMPARATOR
Intervention: Post-vaccination cohort (2017-18)
Number of subjects: 400
Study 34043963 — intervention group
Group type: COMPARATOR
Intervention: 149 confirmed vaccinated men from HYPER2
Number of subjects: 400
Study 34044190 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) scans before and 3 months after surgery
Number of subjects: 0
Study 34044190 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) scans
Number of subjects: 0
Study 34044190 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers and monocyte counts
Number of subjects: 0
Study 34045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography measurement of gastric antral cross-sectional area in supine position
Number of subjects: 192
Study 34045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography measurement of gastric antral cross-sectional area in right lateral decubitus position
Number of subjects: 192
Study 34045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative antral grade
Number of subjects: 192
Study 34045064 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for gastric fluid volume
Number of subjects: 192
Study 34045212 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree-of-worry (DOW) rated on a scale of 1 to 5 (1=minimum worry, 5=maximum worry)
Number of subjects: 6812
Study 34045212 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) rated on a scale of 1 to 5 (1=excellent, 5=poor)
Number of subjects: 6812
Study 34045234 — intervention group
Group type: EXPERIMENTAL
Intervention: M3258, an orally bioavailable, potent, reversible and highly selective LMP7 inhibitor
Number of subjects: 0
Study 34045232 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR inhibitor M4344
Number of subjects: 0
Study 34045239 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing for Lung Health sessions
Number of subjects: 8
Study 34045315 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34045667 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH) treatment over 5 years.
Number of subjects: 114
Study 34045689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention including one boiled egg and 150 ml milk daily 6 days a week for 3 months; psychosocial stimulation including structured play activities and parental counseling for 6 months; routine clinical care.
Number of subjects: 50
Study 34045689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (egg and milk consumption)
Number of subjects: 50
Study 34046008 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34046035 — intervention group
Group type: EXPERIMENTAL
Intervention: UV1 vaccination with GM-CSF as an adjuvant in combination with ipilimumab
Number of subjects: 12
Study 34046035 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 12
Study 34046159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 49
Study 34046424 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro Hand S
Number of subjects: 0
Study 34046424 — intervention group
Group type: COMPARATOR
Intervention: da Vinci Surgical Robot-Assisted Surgery
Number of subjects: 0
Study 34046552 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtually delivered 12-week multidisciplinary rehabilitation programme
Number of subjects: 0
Study 34046552 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34046851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 34046851 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution-based estimates for POEM
Number of subjects: 0
Study 34046851 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution-based estimates for CDLQI
Number of subjects: 0
Study 34046875 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment formulas for responder misclassification
Number of subjects: 0
Study 34046875 — intervention group
Group type: COMPARATOR
Intervention: Unadjusted estimates
Number of subjects: 0
Study 34046915 — intervention group
Group type: COMPARATOR
Intervention: Capmatinib 200 mg (single oral dose)
Number of subjects: 31
Study 34047178 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide and all-trans retinoic acid treatment
Number of subjects: 154
Study 34047700 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based recruitment via Facebook and Instagram advertisements
Number of subjects: 11
Study 34047700 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person recruitment at clinical visits
Number of subjects: 11
Study 34047700 — intervention group
Group type: EXPERIMENTAL
Intervention: Snowball sampling recruitment
Number of subjects: 11
Study 34047700 — intervention group
Group type: EXPERIMENTAL
Intervention: Other recruitment methods
Number of subjects: 11
Study 34047707 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-tier family-oriented care management intervention (8-12 weeks)
Number of subjects: 264
Study 34047707 — intervention group
Group type: COMPARATOR
Intervention: Standardized protocol conducted by trained volunteers (active comparison group)
Number of subjects: 264
Study 34047707 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-tier family-oriented care management intervention
Number of subjects: 264
Study 34047851 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 70
Study 34047851 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 70
Study 34047947 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab 80 mg Q2W
Number of subjects: 3866
Study 34047947 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab 80 mg Q4W
Number of subjects: 3866
Study 34047947 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3866
Study 34047947 — intervention group
Group type: COMPARATOR
Intervention: etanercept 50 mg Q2W
Number of subjects: 3866
Study 34047947 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI
Number of subjects: 3866
Study 34047947 — intervention group
Group type: EXPERIMENTAL
Intervention: DLQI
Number of subjects: 3866
Study 34047953 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 275
Study 34047953 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 275
Study 34047959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (once-weekly)
Number of subjects: 25411
Study 34047959 — intervention group
Group type: EXPERIMENTAL
Intervention: SUSTAIN-6
Number of subjects: 25411
Study 34047959 — intervention group
Group type: EXPERIMENTAL
Intervention: LEADER
Number of subjects: 25411
Study 34047959 — intervention group
Group type: EXPERIMENTAL
Intervention: EXSCEL
Number of subjects: 25411
Study 34047959 — intervention group
Group type: EXPERIMENTAL
Intervention: REWIND
Number of subjects: 25411
Study 34048072 — intervention group
Group type: EXPERIMENTAL
Intervention: KMT2A-AFF1-positivity
Number of subjects: 926
Study 34048072 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 926
Study 34048282 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment with Ifetroban, a potent and selective thromboxane A2 receptor antagonist.
Number of subjects: 0
Study 34048449 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic critical illness (CCI) patients
Number of subjects: 887
Study 34048449 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurity and prolonged mechanical ventilation
Number of subjects: 887
Study 34048449 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of ICU stay
Number of subjects: 887
Study 34048449 — intervention group
Group type: EXPERIMENTAL
Intervention: PCCI patients
Number of subjects: 887
Study 34048449 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cost values for 2017
Number of subjects: 887
Study 34048461 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine for 28 days
Number of subjects: 94
Study 34048497 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus ICT IgG/M lateral flow device (LFD)
Number of subjects: 374
Study 34048509 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor (AM) with personalized daily step goal and resistance exercises
Number of subjects: 50
Study 34048509 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 34048594 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon therapy for more than 6 months
Number of subjects: 12
Study 34048681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance at 10 mg for 21 days of 28-day cycles until progression or unacceptable toxic effects for up to 5 years.
Number of subjects: 108
Study 34048794 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-driven PrEP (2+1+1 dosing)
Number of subjects: 598
Study 34048794 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg)
Number of subjects: 598
Study 34048794 — intervention group
Group type: COMPARATOR
Intervention: Comparison with CohMSM (before PrEP availability)
Number of subjects: 598
Study 34048794 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP only
Number of subjects: 598
Study 34048794 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP and condom
Number of subjects: 598
Study 34048794 — intervention group
Group type: EXPERIMENTAL
Intervention: Condomless anal sex
Number of subjects: 598
Study 34048794 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of male sexual partners
Number of subjects: 598
Study 34048794 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of sex acts with casual male partners (1-4 sex acts in previous 4 weeks)
Number of subjects: 598
Study 34048794 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of sex acts with casual male partners (≥5 sex acts)
Number of subjects: 598
Study 34048794 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of gonorrhoea, chlamydia, and syphilis
Number of subjects: 598
Study 34048901 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training with a pre-training no-feedback run
Number of subjects: 608
Study 34048901 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training for patients
Number of subjects: 608
Study 34048901 — intervention group
Group type: COMPARATOR
Intervention: Neurofeedback training for healthy participants
Number of subjects: 608
Study 34049013 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (10-Hz stimulation, positioned over the left Broca's area)
Number of subjects: 20
Study 34049053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually diverse students (bisexual or other sexual orientation)
Number of subjects: 8531
Study 34049053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisgender female students and gender diverse (GD) students
Number of subjects: 8531
Study 34049053 — intervention group
Group type: EXPERIMENTAL
Intervention: Some sexually diverse (SD) students and gender diverse (GD) students
Number of subjects: 8531
Study 34049308 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial dysfunction assessment
Number of subjects: 28
Study 34049356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-IFN-α2a
Number of subjects: 3
Study 34049356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-IFN-α2b
Number of subjects: 3
Study 34049356 — intervention group
Group type: COMPARATOR
Intervention: Control (no immunotherapy)
Number of subjects: 3
Study 34049362 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (aHSCT)
Number of subjects: 5
Study 34049394 — intervention group
Group type: EXPERIMENTAL
Intervention: Children carrying ≥1 minor allele on β-carotene-15,15'-monooxygenase (BCO1)-rs7501331 (T allele)
Number of subjects: 134
Study 34049394 — intervention group
Group type: EXPERIMENTAL
Intervention: Children carrying ≥1 minor allele on cluster of differentiation 36 (CD36)-rs1527483 (T allele)
Number of subjects: 134
Study 34049394 — intervention group
Group type: EXPERIMENTAL
Intervention: Children carrying ≥1 minor allele on CD36-rs3173798 (C allele)
Number of subjects: 134
Study 34049394 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for dietary lutein (L) and zeaxanthin (Z) intake
Number of subjects: 134
Study 34049582 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplo
Number of subjects: 469
Study 34049582 — intervention group
Group type: EXPERIMENTAL
Intervention: MUD
Number of subjects: 469
Study 34049582 — intervention group
Group type: COMPARATOR
Intervention: MSD
Number of subjects: 469
Study 34049676 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800
Study 34049676 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 1800
Study 34049948 — intervention group
Group type: EXPERIMENTAL
Intervention: Truenat MTB assay
Number of subjects: 1807
Study 34049948 — intervention group
Group type: EXPERIMENTAL
Intervention: Truenat MTB Plus assay
Number of subjects: 1807
Study 34049948 — intervention group
Group type: EXPERIMENTAL
Intervention: Truenat MTB-RIF Dx assay
Number of subjects: 1807
Study 34049948 — intervention group
Group type: COMPARATOR
Intervention: Xpert MTB/RIF assay
Number of subjects: 1807
Study 34050021 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cell analysis using high-dimensional mass cytometry
Number of subjects: 0
Study 34050027 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-displayed trimeric H3 HA vaccine; dosage: as low as 2 ng HA; duration: not specified.
Number of subjects: 0